Cholangiocarcinoma Market Size & Share, by Product Type (Capecitabine, 5-Fluorouracil, Oxaliplatin, Gemcitabine, Cisplatin); Cancer Type (Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma); Therapy Type (Targeted Drug Therapy, Chemotherapy, Immunotherapy); Route of Administration (Oral, Subcutaneous, Intravenous); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-Commerce) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5383
  • Published Date: Nov 20, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Cholangiocarcinoma Market size is expected to surpass USD 1.3 Billion by the end of 2036, growing at a CAGR of 4% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of cholangiocarcinoma was over USD 800 Million. The growth of the market is due to growing infections like liver fluke which will drive market demand. In more than 70 nations across the world, at least 2.4 million individuals are infected and several million more are at danger, particularly in areas where sheep or cattle are raised.

Also, increasingly, combination therapy and the necessity for medications with low side effects are some of the factors projected to propel market expansion. In addition to these, in an effort to enhance the state of cancer therapy, numerous new initiatives are being launched. Numerous studies are being conducted to discover cancer medications and other essentials in order to facilitate treatment for patients. As a result, hospitals and clinics are providing cancer patients with more modern healthcare options, which is creating a lot of growth potential for the cholangiocarcinoma market.

Cholangiocarcinoma Market
Get more information on this report: Request Free Sample PDF

Cholangiocarcinoma Sector: Growth Drivers and Challenges

Growth Drivers

  • New Drug Approvals by Regulatory Bodies- The expansion of the worldwide cholangiocarcinoma market is anticipated to be driven by key market participants obtaining licences from regulatory authorities. The biopharmaceutical company Incyte, for example, announced in April 2020 that the FDA had approved Pemazyre, a kinase inhibitor, for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma that has an FDA-approved test detecting a FGFR2 fusion or other rearrangement. In 2022, the Centre for Drug Evaluation and Research (CDER) authorised 37 new medications. There is a significant variation in the quantity of new pharmaceutical goods that are approved each year. In 2016, there were just over 20 unique pharmaceuticals released, whereas in 2018, there were nearly 60 new products approved. 50 new medication approvals were made in 2021.
  • Raising Knowledge About Cholangiocarcinoma- Rising awareness of cholangiocarcinoma is anticipated to fuel the expansion of the global market for the condition. For example, in March 2022, the non-profit Pancare Foundation saw an opportunity to launch its awareness campaign for biliary cancer in Australia during the month of February, which is globally recognised as Gallbladder and Bile Duct Cancer Awareness Month. To raise awareness of biliary cancer in the general public, the activities include a new clinical trial, support for a biliary cancer research programme, animations describing common signs of the disease, and a new fellowship for biliary cancer research.
  • Growing the Use of Inorganic Growth Techniques- The purchase agreements for cholangiocarcinoma, which are being pursued by major players in the market, are examples of inorganic development tactics that are anticipated to propel the expansion of the worldwide cholangiocarcinoma market during the forecast period. For example, in October 2022, the multi-strategy alternative asset management company Sagard Healthcare announced that it had acquired the rights of TIBSOVO from Agios Pharmaceuticals, Inc., a pharmaceutical company. The FDA has approved TIBSOVO, an oral targeted medication, to treat adult patients with acute myeloid leukaemia (AML) or cholangiocarcinoma (bile duct cancer) who have an isocitrate dehydrogenase-1 (IDH1) mutation.


  • Treatment for cholangiocarcinoma is quite expensive- The high cost of treating cholangiocarcinoma is anticipated to hinder the global cholangiocarcinoma market for the disease. As an illustration, on June 11, 2023, information from the online pharmaceutical encyclopaedia states that Keytruda (pembrolizumab), a medication that belongs to the anti-PD-1 monoclonal antibodies drug class, is frequently used to treat cholangiocarcinoma, breast cancer, cervical cancer, colorectal cancer, and other conditions. Keytruda intravenous solution (25 mg/mL) costs about USD 5,747 for a four-millilitre supply. Furthermore, the same source states that a supply of 14 pemazyre oral pills, each with a dosage of 4.5 mg, costs approximately 19,000 USD.
  • Cholangiocarcinoma diagnosis at an early stage is still extremely difficult, mostly because the illness is asymptomatic in the early stages or presents with vague symptoms.
  • Patients are given a variety of treatments, but for cases that cannot be surgically removed, there is no set standard of care.

Cholangiocarcinoma Market: Key Insights

Base Year


Forecast Year



~ 4%

Base Year Market Size (2023)

 ~ USD 800 Million

Forecast Year Market Size (2036)

 ~ USD 1.3 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Cholangiocarcinoma Segmentation

Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-Commerce)

The retail pharmacy segment is anticipated to hold 40% share of the global cholangiocarcinoma market during the forecast period. The Cholangiocarcinoma (CCA) treatment market is predicted to continue growing because of the increasing availability of both prescription and over-the-counter medications in retail pharmacies. The convenience of being able to buy various medical supplies and fill several prescriptions in one location is probably a big reason why retail pharmacies are becoming more and more popular.  Retail chains are the largest prescription distributors per retail location, dispensing over 138,000 prescriptions annually per store, or almost 50% more than grocers.

Cancer Type (Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma)

Cholangiocarcinoma market from the intrahepatic cholangiocarcinoma segment is estimated to hold largest share of about 58% during the forecast period mainly due to the disease's rising global occurrence. Every year, about 8,000 Americans receive a diagnosis for it. Cholangiocarcinoma affects fewer than six persons per 100,000 in Western countries annually. But cholangiocarcinoma is more common in Southeast Asia, that is, Thailand, South Korea, and China, affecting over six persons out of every 100,000 annually. During the forecast period, the market is anticipated to increase due in part to the presence of several large and mid-sized pharmaceutical suppliers with novel medicines that are nearing the completion of clinical studies.

Our in-depth analysis of the global cholangiocarcinoma market includes the following segments:

          Product Type

  • Capecitabine
  • 5-Fluorouracil
  • Oxaliplatin
  • Gemcitabine
  • Cisplatin  

          Cancer Type

  • Intrahepatic Cholangiocarcinoma
  • Extrahepatic Cholangiocarcinoma

          Therapy Type

  • Targeted Drug Therapy
  • Chemotherapy
  • Immunotherapy

          Route of Administration

  • Oral
  • Subcutaneous
  • Intravenous

          Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Cholangiocarcinoma Industry - Regional Synopsis

North America Market Forecast

Cholangiocarcinoma market in North America region is attributed to hold largest revenue share of about 35% during the forecast period. The growth of the market in the region is due to the growing small and medium-sized businesses that are engaging in R&D to build medical healthcare facilities in the healthcare sector. In addition, people's eating and lifestyle habits are changing, and bile cancer is becoming more common in the area. Every year, about 8,000 Americans receive a diagnosis for it. The growth of the market in this region is result of new medications being approved for sale. A kinase inhibitor called infigratinib, for example, received accelerated approval from the U.S. FDA in May 2021 for adults with previously treated, incurable locally advanced or metastatic cholangiocarcinoma that has a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as identified by an FDA-approved test.

APAC Market Statistic

Cholangiocarcinoma market in the Asia Pacific region is projected to account for 25% of the revenue share by 2036. The growth of the market in this region is because cholangiocarcinoma is becoming more and more popular. The expansion of the market is aided by the rise in awareness campaigns and private investment.

Research Nester
Cholangiocarcinoma Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Cholangiocarcinoma Market

    • Verismo Therapeutics, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Eli Lilly and Company
    • AstraZeneca plc
    • Merck Sharp & Dohme LLC.
    • Basilea Pharmaceutica Ltd.
    • Incyte Corporation
    • Agios Pharmaceuticals Inc.
    • Specialised Therapeutics Asia Pte Ltd (ST)
    • PlantPraxis Biotecnologia
    • Dr. Reddy’s Laboratories Ltd.

In the News

  • Verismo Therapeutics, a clinical-stage CAR T company and pioneer of the novel KIR-CAR platform technology, announced that it had received Fast Track designation from the U.S. Food and Drug Administration (FDA) for SynKIR-110, an investigational new drug administered intravenously for the treatment of mesothelin-expressing mesothelioma, cholangiocarcinoma, and ovarian cancer.
  • AstraZeneca, a global pharmaceutical company, announced that Imfinzi (durvalumab), a human monoclonal antibody that binds to the PD-L1 protein, had been approved in the U.S. by the FDA for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC) in combination with chemotherapy (gemcitabine plus cisplatin).

Author Credits:  Radhika Pawar

  • Report ID: 5383
  • Published Date: Nov 20, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The increasing Research & development and rising awareness about cholangiocarcinoma are the major factors driving the growth of the cholangiocarcinoma market.

The market size of cholangiocarcinoma is anticipated to attain a CAGR of 4% over the forecast period, i.e., 2024-2036.

The major players in the market are Eli Lilly and Company, AstraZeneca, Merck Sharp & Dohme Corp, Basilea Pharmaceutica, Incyte Corporation, Agios Pharmaceuticals, Specialised Therapeutics, PlantPraxis Biotecnologia, Dr. Reddy’s Laboratories, and others.

The retail pharmacy segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Cholangiocarcinoma Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying